IPOs https://www.benzinga.com/views/taxonomy/term/34991 en Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share https://www.benzinga.com/general/biotech/21/05/21130552/gene-therapy-player-vera-therapeutics-prices-ipo-well-below-range-at-11share <ul> <li><strong>Vera Therapeutics Inc</strong>&nbsp;has&nbsp;<a class="editor-rtfLink" href="https://www.globenewswire.com/news-release/2021/05/14/2229627/0/en/Vera-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">priced its 4.35 million share IPO at $11 per share</a>, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The biotech will start trading on NASDAQ from Monday under the ticker &ldquo;VERA.&rdquo;</li> <li>Vera&rsquo;s lead candidate atacicept is a fusion protein to treat IgA nephropathy that recently went through Phase 2a trials.</li> <li>IgAN, ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/21130552/gene-therapy-player-vera-therapeutics-prices-ipo-well-below-range-at-11share alt=Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share>Full story available on Benzinga.com</a></p> Berger's disease Biotech Briefs gene therapy MKGAF MKKGY News VERA Health Care Offerings IPOs General MKGAF DE0006599905 VERA MKKGY News Biotech Health Care Offerings IPOs General Benzinga Fri, 14 May 2021 19:40:39 +0000 Vandana Singh 21130552 at https://www.benzinga.com NerdWallet Files For IPO: Report https://www.benzinga.com/news/21/05/21132320/nerdwallet-files-for-ipo-report <p>Consumer financial advice website NerdWallet has reportedly filed for an IPO.</p> <p><strong>What Happened?</strong>&nbsp;Reuters reported that NerdWallet has confidentially submitted IPO filings to U.S. regulators and hired a team of investment banks led by <strong>Morgan Stanley</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ms#NYSE">MS</a>) to underwrite its IPO process.</p> <p><strong>What It&rsquo;s Important:</strong> The U.S. IPO market has been red-hot for over a year now, and NerdWallet could be the latest in a long list of recent high-profile IPOs. Sources say the company could seek an IPO valuation of up to $5 billion.</p> <p>NerdWallet and other financial technology companies have benefitted from a boom ...</p><p><a href=https://www.benzinga.com/news/21/05/21132320/nerdwallet-files-for-ipo-report alt=NerdWallet Files For IPO: Report>Full story available on Benzinga.com</a></p> COIN INTU MS NerdWallet News IPOs Media COIN US21254S1078 INTU US4612021034 MS US6174464486 News IPOs Media Benzinga Fri, 14 May 2021 17:42:51 +0000 Wayne Duggan 21132320 at https://www.benzinga.com The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts https://www.benzinga.com/general/biotech/21/05/21123935/the-daily-biotech-pulse-cormedix-slumps-on-delay-in-resubmission-of-defencath-nda-apellis-awaits- <p>Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.</p> <h3>Scaling The Peaks</h3> <p>(Biotech Stocks Hitting 52-week Highs May 13)</p> <ul> <li><strong>Alexion Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxn#NASDAQ">ALXN</a>)</li> <li><strong>Novo Nordisk A/S </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>)</li> <li><strong>Vaccitech plc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vacc#NASDAQ">VACC</a>)</li> </ul> <h3>Down In The Dumps</h3> <p>(Biotech Stocks Hitting 52-week Lows May 13)</p> <ul> <li><strong>4D Molecular Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fdmt#NASDAQ">FDMT</a>)</li> <li><strong>ADC Therapeutics SA </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adct#NYSE">ADCT</a>)</li> <li><strong>Accelerate Diagnostics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axdx#NASDAQ">AXDX</a>)</li> <li><strong>Achilles Therapeutics plc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achl#NASDAQ">ACHL</a>)</li> <li><strong>Akouos, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akus#NASDAQ">AKUS</a>) (announced its first-quarter results)</li> <li><strong>Applied Genetic Technologies Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agtc#NASDAQ">AGTC</a>)</li> <li><strong>Aprea Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apre#NASDAQ">APRE</a>)</li> <li><strong>Aquestive Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqst#NASDAQ">AQST</a>)</li> <li><strong>Arcturus Therapeutics Holdings Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>)</li> <li><strong>Atea Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avir#NASDAQ">AVIR</a>)</li> <li><strong>Atreca, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcel#NASDAQ">BCEL</a>)</li> <li><strong>Bellerophon Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blph#NASDAQ">BLPH</a>)</li> <li><strong>Biomea Fusion, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmea#NASDAQ">BMEA</a>)</li> <li><strong>Capricor Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>)</li> <li><strong>Cellectis S.A. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>)</li> <li><strong>ContraFect Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cfrx#NASDAQ">CFRX</a>)</li> <li><strong>Co-Diagnostics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/codx#NASDAQ">CODX</a>)</li> <li><strong>Decibel Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dbtx#NASDAQ">DBTX</a>)</li> <li><strong>Deciphera Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcph#NASDAQ">DCPH</a>)</li> <li><strong>Design Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dsgn#NASDAQ">DSGN</a>)</li> <li><strong>Diffusion Pharmaceuticals Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dffn#NASDAQ">DFFN</a>)</li> <li><strong>Edgewise Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>)</li> <li><strong>Enveric Biosciences, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>)</li> <li><strong>Evoke Pharma, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evok#NASDAQ">EVOK</a>) (<a href="https://www.benzinga.com/general/biotech/21/05/21102045/the-daily-biotech-pulse-merck-reports-positive-keytruda-data-in-breast-cancer-curis-evoke-slump-o">reacted </a> to its first-quarter results)</li> <li><strong>Foghorn Therapeutics Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fhtx#NASDAQ">FHTX</a>)</li> <li><strong>Gain Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ganx#NASDAQ">GANX</a>)</li> <li><strong>Galecto, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glto#NASDAQ">GLTO</a>)</li> <li><strong>Galmed Pharmaceuticals Ltd. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glmd#NASDAQ">GLMD</a>) (announced its first-quarter results)</li> <li><strong>Global Blood Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbt#NASDAQ">GBT</a>)</li> <li><strong>Gracell Biotechnologies Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grcl#NASDAQ">GRCL</a>)</li> <li><strong>Graybug Vision, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gray#NASDAQ">GRAY</a>)</li> <li><strong>Haemonetics Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hae#NYSE">HAE</a>) (announced its first-quarter results)</li> <li><strong>Happiness Biotech Group Limited </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/happ#NASDAQ">HAPP</a>)</li> <li><strong>Harmony Biosciences Holdings, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrmy#NASDAQ">HRMY</a>)</li> <li><strong>Hepion Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hepa#NASDAQ">HEPA</a>)</li> <li><strong>HTG Molecular Diagnostics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htgm#NASDAQ">HTGM</a>)</li> <li><strong>Idera Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idra#NASDAQ">IDRA</a>)</li> <li><strong>Impel NeuroPharma, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>)</li> <li><strong>InflaRx N.V. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifrx#NASDAQ">IFRX</a>)</li> <li><strong>Inhibikase Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ikt#NASDAQ">IKT</a>)</li> <li><strong>Inozyme Pharma, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inzy#NASDAQ">INZY</a>)</li> <li><strong>Instil Bio, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/til#NASDAQ">TIL</a>) (announced its first-quarter results)</li> <li><strong>Iovance Biotherapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iova#NASDAQ">IOVA</a>)</li> <li><strong>Kala Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kala#NASDAQ">KALA</a>)</li> <li><strong>Kamada Ltd. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kmda#NASDAQ">KMDA</a>)</li> <li><strong>Kiniksa Pharmaceuticals, Ltd. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>)</li> <li><strong>Kinnate Biopharma Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knte#NASDAQ">KNTE</a>)</li> <li><strong>Kiromic BioPharma, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krbp#NASDAQ">KRBP</a>)</li> <li><strong>La Jolla Pharmaceutical Company </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ljpc#NASDAQ">LJPC</a>)</li> <li><strong>LogicBio Therapeutics, Inc. </strong> (NASDAQ: NASDAQ: LOGC)</li> <li><strong>Longeveron Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>)</li> <li><strong>Lyra Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyra#NASDAQ">LYRA</a>)</li> <li><strong>MediciNova, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>)</li> <li><strong>Mesoblast Limited </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>)</li> <li><strong>Metacrine, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtcr#NASDAQ">MTCR</a>)</li> <li><strong>NeuBase Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>)</li> <li><strong>NeuroBo Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrbo#NASDAQ">NRBO</a>)</li> <li><strong>NeuroPace, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/npce#NASDAQ">NPCE</a>)</li> <li><strong>NuCana plc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>)</li> <li><strong>Odonate Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/odt#NASDAQ">ODT</a>)</li> <li><strong>Opthea Limited </strong> (NASDAQ: <a ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/21123935/the-daily-biotech-pulse-cormedix-slumps-on-delay-in-resubmission-of-defencath-nda-apellis-awaits- alt=The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts>Full story available on Benzinga.com</a></p> ACHL ADCT AGTC AKUS ALXN AMGN APLS APRE AQST ARCT ATNX AVIR AXDX AZN BCEL BDSI Biotech BLPH BMEA BNGO BPTH CAPR CFRX CLLS CLSN CODX CRMD DBTX DCPH DFFN DSGN Earnings ELOX ENVB EVOK EWTX FDMT FHTX FMTX GANX GBT GLMD GLTO GRAY GRCL HAE HAPP HEPA HOWL HRMY HTGM IBB IDRA IFRX IKT IMPL INZY IOVA KALA KMDA KNSA KNTE KRBP LGVN LJPC LUNG LYRA MESO MNOV MTCR NBSE NCNA News NPCE NRBO NVO ODT OM OPT ORGS ORPH OYST Penny Stocks PHAR PHIO PHVS PLX PLXP PRAX PSTI PTCT PTE QLGN RAIN RARE RETA RGNX RLAY RPHM RXRX SBTX SCPS SLNO SNGX SNSE SONN SQZ TALS TARA TIL TRVI UPC URGN VACC VECT VIVE VLON VOR VRPX WINT XLRN Offerings Small Cap FDA IPOs Top Stories Pre-Market Outlook General RARE AKUS PLX US74365A1016 TIL SCPS CRMD LUNG NPCE GLMD RLAY PTE VIVE ENVB SNGX KNSA IMPL CFRX INZY ADCT AVIR GRCL ARCT BNGO VACC SQZ HRMY ALXN US0153511094 WINT VOR PHAR AQST HOWL HTGM MTCR AMGN US0311621009 URGN SNSE VECT PHIO TALS CAPR ORPH BDSI US09060J1060 SLNO PHVS NRBO TRVI BLPH UPC CLSN US15117N3052 ATNX VLON DBTX HAPP CLLS GRAY IBB US4642875565 IOVA LGVN ORGS BCEL GBT KRBP IDRA US45168K3068 CODX VRPX APRE NBSE RGNX PRAX LJPC US5034594060 KALA GANX OM HEPA OYST PLXP FHTX MNOV US58468P2065 NCNA EWTX KMDA TARA MESO GLTO PSTI US72940R1023 DCPH DSGN PTCT SONN RETA IKT AZN US0463531089 IFRX ACHL AXDX LYRA RAIN KNTE HAE US4050241003 APLS RPHM XLRN QLGN DFFN SBTX NVO US6701002056 ODT BMEA EVOK FMTX OPT FDMT BPTH US09057N1028 ELOX RXRX AGTC Biotech Earnings News Penny Stocks Offerings Small Cap FDA IPOs Top Stories Pre-Market Outlook General Benzinga Fri, 14 May 2021 11:59:10 +0000 Shanthi Rexaline 21123935 at https://www.benzinga.com Vera Therapeutics Announces Pricing of Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21120208/vera-therapeutics-announces-pricing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera"), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $47.85 million. All of the shares are being offered by Vera. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 652,500 shares of its Class A common stock at the initial public offering price, less the underwriting discounts and commissions.<br /></p> <p>The shares are expected to begin trading on the Nasdaq Global Market on May 14, 2021, under the ticker symbol "VERA." The offering is expected ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21120208/vera-therapeutics-announces-pricing-of-initial-public-offering alt=Vera Therapeutics Announces Pricing of Initial Public Offering>Full story available on Benzinga.com</a></p> News VERA IPOs Press Releases Fri, 14 May 2021 00:52:03 +0000 Globe Newswire 21120208 at https://www.benzinga.com Flora Growth Corp. Announces Closing of Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21117993/flora-growth-corp-announces-closing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ" rel="nofollow">FLGC</a>) ("Flora" or the "Company"), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced the closing of its initial public offering of 3,333,333 of its common shares.<br /></p> <p align="justify">On May 11, 2021, the Company&#039;s common shares commenced trading on the Nasdaq Capital Market under the ticker symbol "FLGC&#34;. The initial public offering was priced at the high end of the proposed price range at US$5.00 per share to the public for a total of US$16,666,665 of gross proceeds to the Company.</p> <p align="justify">Boustead Securities, LLC acted as the sole underwriter for the offering (the "Underwriter") with MKM Partners acting as co-Manager. The Underwriter has been granted a 45-day option to purchase up to an additional 500,000 common shares to cover over-allotments at the initial public offering price of $5.00 per share.</p> <p align="justify">The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Boustead Securities, LLC, via email: <a href="https://www.globenewswire.com/Tracker?data=3CSzYmPvktG8OVEWzwxVnrtW2B85DIjREY6ntoYMrTDd86vCu7RR4CJ2NNFcHI9RtXe75LViWVCr_5SMxgg603h3g0HNF9AuglR-ujDo1Ec3yZ4zyor4EmQL4dPRhSW3" rel="nofollow" target="_blank" rel="nofollow">offerings@boustead1828.com</a> or by calling +1 (949) 502-4408 or requested by standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus relating to the offering may be ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21117993/flora-growth-corp-announces-closing-of-initial-public-offering alt=Flora Growth Corp. Announces Closing of Initial Public Offering>Full story available on Benzinga.com</a></p> FLGC News IPOs Press Releases Thu, 13 May 2021 21:13:59 +0000 Globe Newswire 21117993 at https://www.benzinga.com Cannabis M&A Activity At All-Time Highs With Little Signs Of Slowing Down https://www.benzinga.com/markets/cannabis/21/05/21091724/cannabis-m-a-activity-at-all-time-highs-with-little-signs-of-slowing-down <p>Cannabis industry M&amp;A activity continues to boom in 2021. Financial tech firm <strong>Refinitiv </strong>reported a 94% surge in M&amp;A during Q1 2020.</p> <p>The trends continued into May with such companies as&nbsp;<strong>Jushi Holdings Inc.</strong> (CSE: JUSH) (OTC: <a href="https://www.benzinga.com/stock/jushf#OTC" style="color:blue; text-decoration:underline">JUSHF</a>), <strong>Trulieve Cannabis Corp.</strong> (CSE: TRUL) (OTCQX: <a href="https://www.benzinga.com/stock/tcnnf#OTCQX" style="color:blue; text-decoration:underline">TCNNF</a>) and <strong>Green Thumb Industries Inc. </strong>(CSE: GTII) (OTCQX: <a href="https://www.benzinga.com/stock/gtbif#OTCQX" style="color:blue; text-decoration:underline">GTBIF</a>) having&nbsp;announced&nbsp;or completed&nbsp;deals&nbsp;early in the month.</p> <p>U.S. industry experts tell Benzinga that several factors could be sustaining the M&amp;A uptick. Experts say the surge should continue throughout the year, with various sources likely playing a part.</p> <p><strong>Market confidence supported by several factors</strong></p> <p>Confidence in the market is spurring M&amp;A activity, say&nbsp;several sources though the source of the uptick in confidence may vary.<br /> Matthew Kittay, a co-chair of <strong>Fox Rothschild</strong>&#39;s mergers and acquisitions practice group, gives credit to macro-market drivers and industry-specific elements.<br /> U.S. consumer spending and confidence play a significant role. In 2020, legal cannabis sales passed $17.5 billion in the United States, according to <strong>BDSA</strong>.<br /> &quot;Any industry connected to retail is a good acquisition target,&quot; Kittay stated.<br /> He added that market leaders are emerging with cash on the balance sheets to put to work.<br /> &quot;These companies are over-solicited by later-stage investors ...</p><p><a href=https://www.benzinga.com/markets/cannabis/21/05/21091724/cannabis-m-a-activity-at-all-time-highs-with-little-signs-of-slowing-down alt=Cannabis M&amp;A Activity At All-Time Highs With Little Signs Of Slowing Down>Full story available on Benzinga.com</a></p> BDSA Brightfield Group Cannabis Entourage Effect Capital Fox Rothschild Government Green Roads GTBIF JUSHF LYF Food Technologies M&A News Penny Stocks PLNHF Refinitiv Regulations TCNNF VLNCF Small Cap IPOs Markets Interview GTBIF PLNHF TCNNF JUSHF VLNCF News M&A Penny Stocks Government Cannabis Regulations Small Cap IPOs Markets Interview Benzinga Wed, 12 May 2021 20:45:30 +0000 Andrew Ward 21091724 at https://www.benzinga.com NextGen Acquisition Corp II. Announces the Separate Trading of its Class A Ordinary Shares and Redeemable Warrants Commencing May 13, 2021 https://www.benzinga.com/pressreleases/21/05/g21092318/nextgen-acquisition-corp-ii-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-rede <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>BOCA RATON, FL, May 12, 2021 (GLOBE NEWSWIRE) -- NextGen Acquisition Corp II. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGACU#NASDAQ" rel="nofollow">NGACU</a>) (the "Company") today announced that, commencing May 13, 2021, holders of the units sold in the Company&#039;s initial public offering of 38,259,457 units may elect to separately trade the Class A ordinary shares and redeemable warrants included in the units. Those units not separated will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the symbol "NGCAU," and the Class A ordinary shares and redeemable warrants that are separated will trade on Nasdaq under the symbols "NGCA" and "NGCAW," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer &amp; Trust Company, the Company&#039;s transfer agent, in order to separate the units into Class A ordinary shares and redeemable warrants.</p> <p>The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21092318/nextgen-acquisition-corp-ii-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-rede alt=NextGen Acquisition Corp II. Announces the Separate Trading of its Class A Ordinary Shares and Redeemable Warrants Commencing May 13, 2021>Full story available on Benzinga.com</a></p> News NGACU NGCA NGCAU NGCAW IPOs Press Releases Wed, 12 May 2021 20:05:00 +0000 Globe Newswire 21092318 at https://www.benzinga.com Will Bird Be The Word For Investors And Micromobility? What To Know About The Scooter SPAC Deal https://www.benzinga.com/m-a/21/05/21082310/will-bird-be-the-word-for-investors-and-micromobility-what-to-know-about-the-scooter-spac-deal <p>A leading electric micromobility company announced a SPAC deal Wednesday with plans to expand to more cities and new segments.</p> <p><strong>The SPAC Deal: </strong>Bird <a href="https://www.sec.gov/Archives/edgar/data/0001829730/000119312521158298/d469014dex991.htm">announced </a>a deal with<strong> Switchback II Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/swbk#NYSE">SWBK</a>) valuing the company at $2.3 billion.</p> <p>Current Switchback II Corporation shareholders<a href="https://www.sec.gov/Archives/edgar/data/1829730/000119312521158297/d469014dex993.htm"> will own</a> 10.8% of the company after the SPAC merger.</p> <p><strong>About Bird:</strong> Bike is a leader in the shared short-range electric transportation market. The company was founded in 2017, introducing the first-ever shared scooter.</p> <p>Bird operates in 200 cities, according to a press release. The company has had more than 95 million rides from customers from inception to now.</p> <p>The company has hardware and software technology including BirdOS, rider apps, ...</p><p><a href=https://www.benzinga.com/m-a/21/05/21082310/will-bird-be-the-word-for-investors-and-micromobility-what-to-know-about-the-scooter-spac-deal alt=Will Bird Be The Word For Investors And Micromobility? What To Know About The Scooter SPAC Deal>Full story available on Benzinga.com</a></p> Bird e-bikes e-scooters M&A micromobility News scooters SPAC SPACs SWBK IPOs SWBK News M&A IPOs Benzinga Wed, 12 May 2021 14:13:31 +0000 Chris Katje 21082310 at https://www.benzinga.com Global-e Announces Pricing of Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21077997/global-e-announces-pricing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">PETAH-TIKVA, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Global-e Online Ltd. (&#34;Global-e&#34;), the world&#39;s leading platform to enable and accelerate global, direct-to-consumer cross-border e-commerce, today announced the pricing of its initial public offering of 15,000,000 of its ordinary shares at a price of $25 per share.<br /></p> <p>Global-e has granted the underwriters a 30-day option to purchase up to 2,250,000 additional ordinary shares at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on May 12, 2021 under the ticker symbol "GLBE," and the offering is expected to close on May 14, 2021, subject to customary closing conditions.</p> <p>Goldman Sachs &amp; Co. LLC, Morgan Stanley &amp; Co. LLC and Jefferies LLC are serving as lead book-running managers for the offering. Piper Sandler &amp; Co., JMP Securities LLC, KeyBanc Capital Markets Inc. ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21077997/global-e-announces-pricing-of-initial-public-offering alt=Global-e Announces Pricing of Initial Public Offering>Full story available on Benzinga.com</a></p> GLBE News IPOs Press Releases Wed, 12 May 2021 11:00:00 +0000 Globe Newswire 21077997 at https://www.benzinga.com Talaris Therapeutics Announces Closing of Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21069047/talaris-therapeutics-announces-closing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALS#NASDAQ" rel="nofollow">TALS</a>), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol "TALS." All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21069047/talaris-therapeutics-announces-closing-of-initial-public-offering alt=Talaris Therapeutics Announces Closing of Initial Public Offering>Full story available on Benzinga.com</a></p> News TALS Health Care IPOs Markets Press Releases Tue, 11 May 2021 20:01:00 +0000 Globe Newswire 21069047 at https://www.benzinga.com Cannabis Cultivator Flora Growth Announces Nasdaq IPO Valued At Over $16M https://www.benzinga.com/markets/cannabis/21/05/21067764/cannabis-cultivator-flora-growth-announces-nasdaq-ipo-valued-at-over-16m <p>Colombia-based&nbsp;cannabis cultivator and producer <strong>Flora Growth Corp. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) announced its initial public offering price, consisting of 3,333,333 common stock shares.</p> <p>A high-end proposed price range of USD$5 per share to the public would net the company $16,666,665 in funds.</p> <p>Flora&rsquo;s common stock began listing on the Nasdaq Capital Market on Tuesday, with the offering slated to close on May ...</p><p><a href=https://www.benzinga.com/markets/cannabis/21/05/21067764/cannabis-cultivator-flora-growth-announces-nasdaq-ipo-valued-at-over-16m alt=Cannabis Cultivator Flora Growth Announces Nasdaq IPO Valued At Over $16M>Full story available on Benzinga.com</a></p> Cannabis Colombia Cannabis FLGC NASDAQ News Penny Stocks IPOs Markets Interview FLGC News Penny Stocks Cannabis IPOs Markets Interview Benzinga Tue, 11 May 2021 19:48:17 +0000 Andrew Ward 21067764 at https://www.benzinga.com What Investors Should Know About Ginkgo Bioworks SPAC Deal: 'Cell Programming Has The Potential To Impact Every Physical Goods Industry' https://www.benzinga.com/m-a/21/05/21065579/what-investors-should-know-about-ginkgo-bioworks-spac-deal-cell-programming-has-the-potential-to-imp <p>A well seasoned SPAC management team announced a SPAC deal Tuesday to bring a cell programming company public.</p> <p><strong>The SPAC Deal:</strong> Ginkgo Bioworks is <a href="https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-become-a-public-company-and-expand-its-leading-platform-for-cell-programming-301288325.html">going public</a> in a SPAC deal with <strong>Soaring Eagle Acquisition Corp</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srng#NASDAQ">SRNG</a>) that values the company at a pre money equity value of $15 billion.</p> <p>Soaring Eagle Acquisition Corp is a SPAC from Harry Sloan and Jeff Sagansky, a <a href="https://www.benzinga.com/news/20/12/18932542/draftkings-skillz-spac-team-launch-1-5-billion-spinning-eagle-what-investors-should-know?utm_source=dlvr.it&amp;utm_medium=facebook">seasoned SPAC team</a> that previously brought <strong>DraftKings Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>) and <strong>Skillz</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sklz#NYSE">SKLZ</a>) public.</p> <p>The SPAC merger includes&nbsp;an oversubscribed PIPE of $775 million from key investors that included Baillie Gifford, Bain Capital, T. Rowe Price, Ark Investment Management and Cascade Investment, led by Bill Gates.</p> <p>Current Soaring Eagle Acquisition shareholders <a href="https://www.ginkgobioworks.com/wp-content/uploads/2021/05/Ginkgo-Bioworks-Investor-Presentation-May-2021.pdf">will own</a> 10% of the company post merger.</p> <p><strong>About Ginkgo Bioworks:</strong> Building a leading horizontal platform for ...</p><p><a href=https://www.benzinga.com/m-a/21/05/21065579/what-investors-should-know-about-ginkgo-bioworks-spac-deal-cell-programming-has-the-potential-to-imp alt=What Investors Should Know About Ginkgo Bioworks SPAC Deal: &#039;Cell Programming Has The Potential To Impact Every Physical Goods Industry&#039;>Full story available on Benzinga.com</a></p> BLI DKNG Ginkgo Bioworks Harry Sloan Jeff Sagansky M&A MRNA mRNA vaccines News PACB SKLZ SPAC SPACs SRNG TMO IPOs TMO US8835561023 PACB US69404D1081 SRNG MRNA US56804Q1022 DKNG BLI SKLZ News M&A IPOs Benzinga Tue, 11 May 2021 19:29:59 +0000 Chris Katje 21065579 at https://www.benzinga.com Logiq Announces Initial Public Offering of Units in Canada https://www.benzinga.com/pressreleases/21/05/g21057592/logiq-announces-initial-public-offering-of-units-in-canada <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Logiq, Inc. ("<strong>Logiq</strong>" or the "<strong>Company</strong>") (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LGIQ#OTCQX" rel="nofollow">LGIQ</a>), a global provider of award-winning eCommerce and fintech solutions, has filed an amended and restated preliminary prospectus (the "<strong>Preliminary Prospectus</strong>") for a proposed initial public offering (the "<strong>Offering</strong>") of units of the Company (the "<strong>Units</strong>") in Canada.  Each Unit will consist of one share of common stock of the Company (a "<strong>Unit Share</strong>") and one purchase warrant of the Company (each, a "<strong>Warrant</strong>"). Each Warrant is exercisable to acquire one share of common stock of the Company (a "<strong>Warrant Share</strong>"). The number of Units to be sold, the offering price of the Units and the terms of the Warrants (including the exercise price and expiry term) will be determined in the context of the market.</p> <p align="justify">The Offering is being conducted by <a href="https://www.globenewswire.com/Tracker?data=J0xaMaAtPIoTV2EgGbv7KbtHvan-SaMn-3QBjONhtFZZGwjVIGzGVt67O57gsOr4-ZSz4ewVQKLKc4ZoKlpN_5gKHIiStEc3xlq5eQddYdQ=" rel="nofollow" target="_blank" rel="nofollow">Research Capital Corporation</a> as the lead agent and sole bookrunner (the "<strong>Agent</strong>"). The Preliminary Prospectus has been filed with the securities regulatory authorities in each of the provinces of Canada (other than Quebec).</p> <p align="justify">The Company has granted the Agent an option (the " <strong>Over-Allotment Option </strong>") to cover over-allotments and for market stabilization purposes, exercisable in whole or in part at the sole discretion of the Agent, at any time up to 30 days from the closing of the Offering, to increase the size of the Offering by up to 15% of the number of Units (and/or the components thereof) sold pursuant to the Offering, on the same terms and conditions of the Offering.</p> <p align="justify">The net proceeds of the Offering will be used for development of additional data analytics tools, sales generation and marketing, and for working capital requirements and other general corporate purposes.</p> <p align="justify">The closing of the Offering is currently expected to be on or about the week of June 7, 2021, or on such date as the Agent and the Company may agree upon, and is subject to certain conditions including, but not limited to the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the NEO Exchange (the "<strong>NEO</strong>") in Canada.</p> <p align="justify">The Company has received conditional approval to list its common stock, including the Unit Shares being distributed under the prospectus, the Warrant Shares issuable upon exercise of the Warrants, any common stock and Warrant Shares issued upon exercise of the Over-Allotment Option and upon exercise of ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21057592/logiq-announces-initial-public-offering-of-units-in-canada alt=Logiq Announces Initial Public Offering of Units in Canada>Full story available on Benzinga.com</a></p> LGIQ News IPOs Press Releases Tue, 11 May 2021 12:31:00 +0000 Globe Newswire 21057592 at https://www.benzinga.com Flora Growth Corp. Announces Pricing of Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21055920/flora-growth-corp-announces-pricing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ" rel="nofollow">FLGC</a>) ("Flora" or the "Company"), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced the pricing of its initial public offering of 3,333,333 shares of its common stock, at the high end of the proposed price range of US$5.00 per share to the public for a total of US$16,666,665 of gross proceeds to the Company.<br /></p> <p align="justify">The common stock is expected to begin trading on the Nasdaq Capital Market today under the symbol &#34;FLGC.&#34; The offering is expected to close on May 13, 2021, subject to customary closing conditions. Boustead Securities, LLC acted as the sole underwriter for the offering (the "Underwriter") with MKM Partners acting as co-Manager. The Underwriter has been granted an overallotment option to purchase up to an additional 500,000 Common Shares in the next 45 days at the offering price of $5.00 per share.</p> <p align="justify">The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Boustead Securities, LLC, via email: <a href="https://www.globenewswire.com/Tracker?data=s0X_O7PWfyHcWA6p6Zrq1CBvzefgvRLpYbHsEBm6WeTSS7c-KJqpLUmEW8zMGkk5G8EKgz4jbC4jk3kfTHuzLCW9FBlA6CVLMOgXBTXCLmq_y-W7dfVo8NupJlU_a6op" rel="nofollow" target="_blank" rel="nofollow">offerings@boustead1828.com</a> or by calling +1 (949) 502-4408 or requested by standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus, when available, relating to ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21055920/flora-growth-corp-announces-pricing-of-initial-public-offering alt=Flora Growth Corp. Announces Pricing of Initial Public Offering>Full story available on Benzinga.com</a></p> FLGC News IPOs Press Releases Tue, 11 May 2021 12:00:00 +0000 Globe Newswire 21055920 at https://www.benzinga.com Oatly Group AB Launches Initial Public Offering https://www.benzinga.com/pressreleases/21/05/g21054359/oatly-group-ab-launches-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">MALMÖ, Sweden, May 11, 2021 (GLOBE NEWSWIRE) -- Oatly Group AB ("Oatly") announced today that it has commenced an initial public offering of 84,376,000 American Depositary Shares ("ADSs"), each representing one ordinary share offered by Oatly and certain selling shareholders. The underwriters of the offering will also have a 30-day option to purchase up to an additional 12,656,400 ADSs from the selling shareholders at the initial public offering price. The initial public offering price is currently estimated to be between $15.00 and $17.00 per share. Oatly has applied to list its ADSs on the Nasdaq Global Select Market under the ticker symbol "OTLY."<br /></p> <p>Morgan Stanley, J.P. Morgan and Credit Suisse are acting as lead book-running managers for the offering. Barclays, Jefferies, BNP PARIBAS, BofA Securities, Piper Sandler and RBC Capital Markets are acting as book-running managers. Rabo Securities, William Blair, Guggenheim Securities, Truist ...</p><p><a href=https://www.benzinga.com/pressreleases/21/05/g21054359/oatly-group-ab-launches-initial-public-offering alt=Oatly Group AB Launches Initial Public Offering>Full story available on Benzinga.com</a></p> News IPOs Press Releases Tue, 11 May 2021 10:59:51 +0000 Globe Newswire 21054359 at https://www.benzinga.com